Soft tissue infections with atypical mycobacteria in two patients with inflammatory rheumatic diseases using TNF-inhibitors and/or Leflunomide

Acta Clinica Belgica

Volumn 66, Issue 2, 2011, Pages 144-147

  Steyaert, S ^a   Stappaerts, G ^a   Mareen, P ^a   Dierick, J ^a  

^a AZ Maria Middelares   (Belgium)

Author keywords

Antimycobacterial therapy; Disease Modifying Anti Rheumatic Drugs (DMARD's); Leflunomide; Mycobacterium chelonae abscessus complex; Mycobacterium marinum; TNF Inhibitors

Indexed keywords

AMIKACIN; CLARITHROMYCIN; COLCHICINE; ETANERCEPT; ETHAMBUTOL; FLUCLOXACILLIN; LEFLUNOMIDE; LEVOFLOXACIN; OFLOXACIN; PIROXICAM; RIFABUTIN; RIFAMPICIN; TRIAMCINOLONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; ISOXAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CELLULITIS; FEMALE; HUMAN; MYCOBACTERIUM; PARONYCHIA; PERIARTHRITIS; PROTEIN ELECTROPHORESIS; RHEUMATOID ARTHRITIS; SOFT TISSUE INFECTION; SPONDYLITIS; TUBERCULIN TEST; ANKYLOSING SPONDYLITIS; ATYPICAL MYCOBACTERIOSIS; DRUG ANTAGONISM; DRUG EFFECT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM MARINUM; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SKIN;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLARITHROMYCIN; ETHAMBUTOL; FEMALE; HUMANS; ISOXAZOLES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM MARINUM; RISK FACTORS; SKIN; SOFT TISSUE INFECTIONS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTORS;

EID: 79960948519     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.2.2062537     Document Type: Article

References (19)

1. Freudenberger RS, Simafranca SM. Cutaneous infection with rapidly-growing mycobacterial infection following heart transplant: a case report and review of the literature. Transplant Proc. 2006; 38: 1526-1529.
2. Mateo L, Rufí G, Nolla JM, Alcaide F. Mycobacterium chelonae tenosynovitis of the hand. Semin Arthritis Rheum. 2004; 34: 617-622. (Pubitemid 39643124)
3. Jacobs JW, Creemers MC, van Agtmael MA et al. TNF-blocking drugs and infection; recommendations for daily practice. Ned Tijdschr Geneeskd 2007 10; 151: 588-593. (Pubitemid 46489974)
4. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006: 2368-2376. (Pubitemid 44204996)
5. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment Thorax. 2005; 60: 800-805.
6. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during antitumour necrosis factor-alpha treatment of infl ammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 19-30. (Pubitemid 350212629)
7. Fox RI, Herrmann ML, Frangou CG et al. Mechanism of Action for Lefl unomide in Rheumatoid Arthritis. Clin Immunol 1999; 93: 198-208.
8. Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Lefl unomide-Associated Infections in Rheumatoid Arthritis. J Rheumatol. 2007; 34: 2201-2203. (Pubitemid 350076879)
9. Salliot C, Gossec L, Ruyssen-Witrand A et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford). 2007; 46: 327-334. (Pubitemid 46189796)
10. Chastain MA, Buckley J, Russo GG. Mycobacterium chelonae/abscessus complex infection in a liver transplant patient. Int J Dermatol 2001; 40: 769-774. (Pubitemid 34051445)
11. Wallace RJ, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166: 405-412.
12. Wallace RJ, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993; 119(6): 482-486. (Pubitemid 23310109)
13. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001; 43: 163-168. (Pubitemid 34211095)
14. Sanford JP. The Sanford guide to antimicrobial therapy 2008-2009.
15. Wallace RJ, Brown-Elliot B, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecylcine (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-3167.
16. Inderlied CB, Pfyffer GE. Susceptibility test methods: mycobacteria. Manual of clinical microbiology, 8th edition. ASM press, Washington DC.
17. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA Statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
18. Rallis E, Koumantaki-Mathioudaki E, Frangoulis E, Chatziolou E, Katsambas A. Severe sporotrichoid fish tank granuloma following infl iximab therapy. Am J Clin Dermatol 2007; 8(6): 385-388. (Pubitemid 350174541)
19. Fallon JC, Patchett S, Gulmann C, Murphy GM. Mycobacterium marinum infection complicating Crohn's disease, treated with infl iximab. Clin Exp Dermatol 2008; 33(1): 43-45. (Pubitemid 350308531)